Home » Blog » Cpop Pharmacy Client Agreement

Cpop Pharmacy Client Agreement

(Last Updated On: September 16, 2021)

Information on these differences is presented in the following tables: On a snapshot day in 2017, nearly 50,000 patients received drug therapy treatment for their opioid dependence at 2,732 dosing points across Australia. For each customer, an individual daily dosage record must be recorded. A model dosing dataset (Word 244KB) is available in the department. Each dose or any unmonitored dose administered should be recorded by the client at the time of dosing. The combination of buprenorphine-naloxone is a sublingual tablet or film containing buprenorphine hydrochloride and naloxone hydrochloride [1]. Buprenorphine-naloxone is recommended to be given to buprenorphine in most patients [3]. This is due to the fact that the combined product, when taken as intended by loosening the tablet or film under the tongue, acts as if it were buprenorphine alone. However, if the combination product is injected, naloxone may block the effect of buprenorphine and increase opioid withdrawal symptoms. This reduces the risk that those who receive buprenorphine naloxone to take away will inject it or sell it to others for injection [2, 3, 4]. At the end of each month, a summary report (Word 877KB) on the dosage of patients for the month must be submitted to the Ministry of Health. Before each dose, the original recipe and the registration of the client`s dosage should be checked personally. You can find information about the AIHW`s privacy policy on the privacy page.

Approved electronic systems can be used to record the customer`s dosage….

Topics

  • No categories